NCT06439836 2026-03-18
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
National Cancer Institute (NCI)
Phase 1 Recruiting
National Cancer Institute (NCI)
Mayo Clinic
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
University of Southern California